Co-Authors
This is a "connection" page, showing publications co-authored by Ioana Agache and Torsten Zuberbier.
Connection Strength
1.659
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy. 2021 03; 76(3):648-676.
Score: 0.233
-
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy. 2021 03; 76(3):689-697.
Score: 0.226
-
Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1). J Thorac Dis. 2019 Aug; 11(8):3633-3642.
Score: 0.209
-
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy. 2011 Apr; 66(4):458-68.
Score: 0.114
-
Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021 10; 76(10):2952-2964.
Score: 0.061
-
ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper. Allergy. 2021 06; 76(6):1624-1628.
Score: 0.059
-
Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus. Allergy. 2021 08; 76(8):2354-2366.
Score: 0.059
-
Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. Int Arch Allergy Immunol. 2021; 182(4):324-338.
Score: 0.058
-
Spices to Control COVID-19 Symptoms: Yes, but Not Only…. Int Arch Allergy Immunol. 2021; 182(6):489-495.
Score: 0.057
-
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020 10; 75(10):2440-2444.
Score: 0.057
-
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020; 4:53-68.
Score: 0.056
-
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020 07; 75(7):1546-1554.
Score: 0.056
-
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy. 2019; 9:16.
Score: 0.051
-
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. Allergy. 2018 08; 73(8):1622-1631.
Score: 0.048
-
CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report. Clin Transl Allergy. 2017; 7:37.
Score: 0.046
-
EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology. 2017 Sep 01; 55(3):202-210.
Score: 0.046
-
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project). Allergy. 2018 Jan; 73(1):77-92.
Score: 0.046
-
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017 Oct; 140(4):950-958.
Score: 0.045
-
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017 Sep; 72(9):1297-1305.
Score: 0.045
-
Google Trends terms reporting rhinitis and related topics differ in European countries. Allergy. 2017 Aug; 72(8):1261-1266.
Score: 0.044
-
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016; 6:47.
Score: 0.044